differentiated thyroid cancer
Oncology · 2015–2018
2decisions
2medicines
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenvatinib Locally advanced or metastatic differentiated thyroid cancer that is refractory to radioactive iodine, in patients for whom surgery is inappropriate and… | Jul 2018 | Recommended with restriction | none received |
| sorafenib Locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer (RAI-R DTC). | Mar 2015 | Deferred | 2 individuals Rare Cancer Australia |
Who spoke
Rare Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.